Skip to main content
Premium Trial:

Request an Annual Quote

Markers Short Reads: Apr 1, 2003

Premium

Genome Canada secured an additional C$75 million from the government to continue investing in genomics and proteomics programs throughout the country.

According to Ralph Tate, NIAID budget officer, this year the institute primarily responsible for bioterror-related research will spend $45-50 million on overall genomics research. Of that, $25-30 million will go to sequencing projects and $12-15 million to functional genomics. Next year, NIAID’s total spending on genomics will jump to $100 million.

Australia’s Benitec and North Carolina-based Tranzyme will collaborate to develop gene silencing and gene delivery technologies.

Ardais, the clinical genomics company in Lexington, Mass., swept up $13.4 million in a new round of financing.

A hearing is scheduled this month in Hartford, Conn., in the PCR-related lawsuit launched by Applied Biosystems against MJ Research.

In the crystal ball category, a Front Line report says the worldwide proteomics market will reach $2.68 billion by 2008. Kalorama Information issued a separate study of the microarray industry, estimating that it will be more than $5 billion by 2010.

They say only bankruptcy lawyers make money in an economy like this, but genomics M&A teams must be making a fortune these days too:

Invitrogen is to buy PanVera from Vertex Pharmaceuticals for $95 million in cash.

Genomic Solutions, now a subsidiary of Harvard Bioscience, offered $8.3 million in cash to snap up microarray firm GeneMachines.

Gene Logic announced it will swallow TherImmune Research, a drug development CRO, for $52 million in cash and stock.

Agencourt Bioscience agreed to buy GenomeVision Services, the fee-for-service sequencing center unit of Genome Therapeutics. That division sequenced about two percent of the human genome for the HGP. GTC expected some 60 people to lose their jobs in the transfer.

In a show of scrappy self-preservation, Caliper Technologies fended off an unsolicited acquisition offer by LB Acquisitions.

There can’t be much that would inspire NHGRI to use the term “cowabunga,” but apparently, the bovine genome has what it takes. The institute announced that, pending additional funds, sequencing will start at Baylor in September. NHGRI has agreed to pony up $25 million — half the expected cost — if the genome center can round up the rest, which it’s trying to do from state and other resources.

Charles River Proteomic Services, the fee-for-service joint venture between Charles River Laboratories and Proteome Systems, is scheduled to open this month at facilities in Worcester, Mass.

Novartis is having good luck moving employees to its new Cambridge, Mass., research headquarters. According to the Boston Globe, more than 70 percent of Novartis employees (and about 90 percent of more senior-level staff) who were asked to relocate accepted the offer. Dalia Cohen, one of the first to agree to the move, will be head of the functional genomics section.

The Michigan Life Sciences Corridor, which is sponsoring a one-day conference this month, took a budget hit. The state’s governor cut $12.5 million from the organization, which has a $45 million allocation. But it wasn’t entirely bad news: original plans were to cut $25 million.

A Harris poll found that 60 percent of US adults could accurately answer the question, “What is DNA?,” compared to 21 percent in a 1996 NSF poll.

It’s what you’ve all been waiting for: LAB21, a team of scientists based at New York’s Stony Brook University, released a genome-based facial cream. Users send in DNA samples, and a custom cream — 1.7 oz for $250 — is designed from genotype results.

 

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.